Sera Prognostics, Inc. (SERA) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended March 31, 2026. Sera Prognostics, Inc. is a women's health company focused on developing and commercializing blood-based biomarker tests, primarily the PreTRM test, which predicts the risk of spontaneous preterm birth. The company operates as a single segment and is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $14,000 | $38,000 |
| Net Loss | $(8,399,000) | $(8,187,000) |
| Loss Per Share (Basic & Diluted) | $(0.17) | $(0.20) |
| Operating Expenses | $9,374,000 | $9,288,000 |
| Cash and Cash Equivalents | $4,175,000 | $5,230,000 |
| Marketable Securities | $82,591,000 | $91,836,000 |
| Total Liquidity (Cash + Securities) | $86,766,000 | $97,066,000 |
| Accumulated Deficit | $(320,121,000) | $(287,981,000) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by $24,000 (63%) to $14,000, primarily due to lower test volume recognition.
- Operating Expenses: Total operating expenses increased slightly by $86,000.
- Selling and Marketing: Increased by $542,000 (37%) due to strategic hiring of commercial personnel.
- Research and Development: Decreased by $304,000 (9%) due to reduced consulting and bioinformatics costs.
- General and Administrative: Decreased by $154,000 (3%), driven by lower stock-based compensation.
- Investing Activities: Net cash provided by investing activities was $8.985 million, a significant shift from the $44.8 million used in Q1 2025. This was driven by $10 million in proceeds from maturities of marketable securities versus heavy purchases in the prior year.
- Stock-Based Compensation: Total expense decreased to $835,000 from $1.493 million in the prior year.
Guidance, Outlook, and Strategic Updates
Strategic Prioritization and Workforce Reduction: On May 6, 2026 (subsequent to the reporting period), the company announced a strategic shift to reallocate resources from R&D to the commercialization of the PreTRM test. This includes a workforce reduction of 14 employees (approximately 18% of the workforce), including the departure of the Chief Data Officer and Chief Information Officer. The company estimates $1.3 million in severance costs to be incurred in Q2 and Q3 2026.
Cost Savings Outlook: Management anticipates meaningful cost savings of approximately $9.6 million in 2027, with projected decreases in cash expenses of 35% in R&D and 25% in G&A.
Liquidity and Runway: With the new cost structure, management expects existing cash and cash equivalents to fund operations and capital expenditures through 2029.
Clinical Evidence: The company highlighted the publication of the PRIME study in January 2026, which demonstrated a 20% reduction in NICU admissions and a 56% reduction in babies born before 32 weeks. This data supports the company's value proposition to payers.
Capital Markets: The company entered into a new At-The-Market (ATM) sales agreement on March 18, 2026, allowing for the sale of up to $40.0 million of Class A common stock.
Investor Verification Checklist
- Severance Impact: Verify the timing and magnitude of the $1.3 million severance charge in upcoming quarterly reports (Q2/Q3 2026).
- Revenue Recognition: Monitor the impact of the strategic shift on revenue growth, specifically regarding payer contracts and the Elevance Health collaboration.
- Cost Reduction Execution: Track the realization of the projected $9.6 million in 2027 cost savings against actual operating expenses.
- Liquidity Management: Review the utilization of the new ATM facility and the drawdown of marketable securities to fund operations.
- Regulatory Landscape: Assess ongoing risks related to FDA regulation of Laboratory Developed Tests (LDTs) and potential impacts on the PreTRM test commercialization.